`
`
`
`
`
`Entered: November 28, 2017
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_______________
`PAR PHARMACEUTICAL, INC. AND INTELGENX CORP.
`Petitioner,
`
`v.
`
`MONOSOL RX, LLC,
`Patent Owner.
`_______________
`
`Case IPR2017-01557
`Patent 8,603,514 B2
`_______________
`
`
`Before ERICA A. FRANKLIN, TINA E. HULSE, and
`CHRISTOPHER G. PAULRAJ, Administrative Patent Judges.
`
`
`PETITIONERS’ REQUEST FOR REFUND OF POST-INSTITUTION FEE
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2017-01557
`Patent 8,603,514 B2
`
`
`On June 9, 2017, Par Pharmaceutical, Inc. (“Par”) and IntelGenx Corp.
`
`(“IntelGenx”) (collectively “Petitioners”) filed a Petition for Inter Partes Review
`
`(IPR2017-01557) seeking review of claims 1-3, 9, 15, 62-65, 69-73, and 75 of U.S.
`
`Patent No. 8,603,514. Pursuant to 37 C.F.R. §42.15(a)(2) and (4), Petitioners’ paid
`
`fees totaling $23,000, which included a $14,000 payment for the post-institution
`
`fee.
`
`On October 20, 2017, the Patent Trial and Appeal Board (“the Board”)
`
`denied institution of the Petition. (Paper 11).
`
`Therefore, because the Petition for Inter Partes review was filed after March
`
`19, 2013, and the proceeding was not instituted, Petitioner is entitled to request a
`
`refund of the post-institution fee that was previously paid. See, e.g., 78 Fed. Reg.
`
`4212, 4233 (Jan. 18, 2013), available at http://www.gpo.gov/fdsys/pkg/FR-2013-
`
`01-18/pdf/2013-00819.pdf (“The entire post-institution fee would be returned to
`
`the petitioner if the Office does not institute a review.”).
`
`Upon review and approval of the request, Petitioner respectfully asks the
`
`Board to credit $14,000 to Petitioners’ by depositing such amount into PTO
`
`Deposit Account No. 506269 of Latham & Watkins LLP.
`
`
`
`
`
`
`
`
`
`1
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2017-01557
`Patent 8,603,514 B2
`
`
`Date: November 28, 2017
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`By: /Daniel G. Brown/
`Daniel G. Brown (Reg. No. 54,005)
`Latham & Watkins LLP
`885 Third Avenue
`New York, NY 10022-4834
`Tel: (212) 906-1200
`Fax: (212) 751-4864
`daniel.brown@lw.com
`
`Jonathan M. Strang (Reg. No. 61,724)
`Latham & Watkins LLP
`555 Eleventh Street NW
`Suite 1000
`Washington, DC 20004-1304
`Tel: (202) 637-2200
`Fax: (202) 637-2201
`jonathan.strang@lw.com
`
`Counsel for Petitioners
`Par Pharmaceutical, Inc.
`IntelGenx Corp.
`
`
`
`2
`
`
`
`Case IPR2017-01557
`Patent 8,603,514 B2
`
`
`CERTIFICATE OF SERVICE
`Pursuant to 37 C.F.R. § 42.6(e), I certify that on this 28th day of November,
`
`2017, a true and correct copy of the foregoing PETITIONERS’ REQUEST FOR
`
`REFUND was served by electronic mail on Patent Owner’s lead counsel at the
`
`following email address:
`
`Harold H. Fox
`Steptoe & Johnson LLP
`1330 Connecticut Avenue, NW
`Washington, DC 20036-1795
`Tel: (202) 429-6284
`Fax: (202) 429-3902
`hfox@steptoe.com
`514MIPR@steptoe.com
`
`
`
`By: /Daniel G. Brown/
`
`
`
`
`
`
`Daniel G. Brown (Reg. No. 54,005)
`Latham & Watkins LLP
`885 Third Avenue
`New York, NY 10022-4834
`212-906-1200; 212-751-4864 (Fax)
`
`Counsel for Petitioner
`Par Pharmaceutical, Inc.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`3
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`